Eli Lilly and Co said on Tuesday it would supply 400,000 tablets of its COVID-19 treatment, to be used with Gilead's remdesivir, to India as the country fights a raging pandemic that has morgues and hospitals overflowing.
With 3.45 million active cases, India recorded 357,229 new infections over the last 24 hours, while deaths rose 3,449 for a count of 222,408, health ministry data showed.
-
-
NDTV World Summit 2026: What To Watch Out For | PM Modi, Jaishankar, AI And Global Power Shifts -
A World Between Orders: What To Expect At NDTV World Summit 2026 -
Andrew Ng On AI At Scale: Building The Intelligence Economy | NDTV World Summit 2026 -
NDTV World Summit 2026: Behind The Scenes As Ayush And Vedika Preview Two-Day Mega Event -
Who Is Rajiv Mehta? Lilavati Hospital Trustee To Speak At NDTV World Summit 2026 -
Ex-CIA Director To Decode 'War In Times Of AI' At NDTV World Summit -
Alain Ebobisse, Africa50 CEO, To Attend NDTV World Summit 2026. All About Him -
Kriti Sanon At NDTV World Summit: A Look At Her Career And Business Ventures -
Ex-CIA Director To Decode 'War In Times Of AI' At NDTV World Summit -
Who Is Vikram Rai, CEO, South Asia GE Aerospace, Set To Attend The NDTV World Summit 2026
The drugmaker said it will work urgently to increase the supply multifold over the coming weeks.
On Monday, the country's drug regulator gave emergency use approval to Lilly's treatment, baricitinib, for its use in hospitalized COVID-19 patients requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.
The drug will be used in combination with Gilead Sciences's COVID-19 drug remdesivir.
Lilly is offering donations of its rheumatoid arthritis drug baricitinib for COVID-19 treatment to the Indian government through aid organization Direct Relief.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Track Latest News Live on NDTV.com and get news updates from India and around the world
